Acetylcholine Receptor (AChR) Antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 working days
DelveInsight’s, “Acetylcholine Receptor (AChR) Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Acetylcholine Receptor (AChR) Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Acetylcholine Receptor (AChR) Antagonists: Overview
Acetylcholine receptor (AChR) has long been known through pharmacological and electrophysiological studies as an operational entity with which acetylcholine interacts to cause a change in the ion permeability of excitable membranes. Muscarinic receptor antagonists (MRAs) function by competitively blocking the cholinergic response manifested by acetylcholine (ACh) binding muscarinic receptors on exocrine glandular cells, cardiac muscle cells, and smooth muscle cells. Therefore, MRAs are heavily involved with the parasympathetic nervous system and act on different types of muscarinic receptors resulting in a wide array of clinical indications. Current literature suggests involvement of nicotinic acetylcholine receptors (nAChRs) in major depression.
'Acetylcholine Receptor (AChR) Antagonists - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acetylcholine Receptor (AChR) Antagonists pipeline landscape is provided which includes the disease overview and Acetylcholine Receptor (AChR) Antagonists treatment guidelines. The assessment part of the report embraces, in depth Acetylcholine Receptor (AChR) Antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acetylcholine Receptor (AChR) Antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Acetylcholine Receptor (AChR) Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acetylcholine Receptor (AChR) Antagonists Emerging Drugs
AXS-05 has received Breakthrough Therapy designation from the FDA for both major depressive disorder and Alzheimer’s disease agitation. In April 2021, Axsome Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for AXS-05 for the treatment of major depressive disorder (MDD), and has granted the application Priority Review.
Further product details are provided in the report……..
Acetylcholine Receptor (AChR) Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Acetylcholine Receptor (AChR) Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Acetylcholine Receptor (AChR) Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acetylcholine Receptor (AChR) Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acetylcholine Receptor (AChR) Antagonists drugs.
Acetylcholine Receptor (AChR) Antagonists Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Acetylcholine Receptor (AChR) Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Acetylcholine Receptor (AChR) Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Acetylcholine Receptor (AChR) Antagonists: Overview
Acetylcholine receptor (AChR) has long been known through pharmacological and electrophysiological studies as an operational entity with which acetylcholine interacts to cause a change in the ion permeability of excitable membranes. Muscarinic receptor antagonists (MRAs) function by competitively blocking the cholinergic response manifested by acetylcholine (ACh) binding muscarinic receptors on exocrine glandular cells, cardiac muscle cells, and smooth muscle cells. Therefore, MRAs are heavily involved with the parasympathetic nervous system and act on different types of muscarinic receptors resulting in a wide array of clinical indications. Current literature suggests involvement of nicotinic acetylcholine receptors (nAChRs) in major depression.
'Acetylcholine Receptor (AChR) Antagonists - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acetylcholine Receptor (AChR) Antagonists pipeline landscape is provided which includes the disease overview and Acetylcholine Receptor (AChR) Antagonists treatment guidelines. The assessment part of the report embraces, in depth Acetylcholine Receptor (AChR) Antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acetylcholine Receptor (AChR) Antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Acetylcholine Receptor (AChR) Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Acetylcholine Receptor (AChR) Antagonists.
This segment of the Acetylcholine Receptor (AChR) Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acetylcholine Receptor (AChR) Antagonists Emerging Drugs
- AXS-05: Axsome Therapeutics
AXS-05 has received Breakthrough Therapy designation from the FDA for both major depressive disorder and Alzheimer’s disease agitation. In April 2021, Axsome Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for AXS-05 for the treatment of major depressive disorder (MDD), and has granted the application Priority Review.
- KarXT: Karuna Therapeutics
Further product details are provided in the report……..
Acetylcholine Receptor (AChR) Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Acetylcholine Receptor (AChR) Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Acetylcholine Receptor (AChR) Antagonists
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Acetylcholine Receptor (AChR) Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acetylcholine Receptor (AChR) Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acetylcholine Receptor (AChR) Antagonists drugs.
Acetylcholine Receptor (AChR) Antagonists Report Insights
- Acetylcholine Receptor (AChR) Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Acetylcholine Receptor (AChR) Antagonists drugs?
- How many Acetylcholine Receptor (AChR) Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acetylcholine Receptor (AChR) Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acetylcholine Receptor (AChR) Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acetylcholine Receptor (AChR) Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Kineta
- Axsome Therapeutics
- Karuna Therapeutics
- Bionomics
- Apnimed
- Lyndra Therapeutics
- KCP506
- AXS-05
- KarXT
- BNC210
- AD-109
- LYN-014
Introduction
Executive Summary
Acetylcholine Receptor (AChR) Antagonists: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
KarXT: Karuna Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
AD-109: Apnimed
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
KCP506: Kineta
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Acetylcholine Receptor (AChR) Antagonists Key Companies
Acetylcholine Receptor (AChR) Antagonists Key Products
Acetylcholine Receptor (AChR) Antagonists- Unmet Needs
Acetylcholine Receptor (AChR) Antagonists- Market Drivers and Barriers
Appendix
Executive Summary
Acetylcholine Receptor (AChR) Antagonists: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
KarXT: Karuna Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
AD-109: Apnimed
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
KCP506: Kineta
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Acetylcholine Receptor (AChR) Antagonists Key Companies
Acetylcholine Receptor (AChR) Antagonists Key Products
Acetylcholine Receptor (AChR) Antagonists- Unmet Needs
Acetylcholine Receptor (AChR) Antagonists- Market Drivers and Barriers
Appendix
LIST OF TABLES
Table 1 Total Products for Acetylcholine Receptor (AChR) Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Acetylcholine Receptor (AChR) Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Acetylcholine Receptor (AChR) Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Acetylcholine Receptor (AChR) Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
